Literature DB >> 2566537

A study of the anticholinergic activity of terfenadine in normal volunteers.

R Vargas1, F G McMahon, J R Ryan.   

Abstract

The anticholinergic effects of single doses of terfenadine, chlorpheniramine and atropine on salivary flow were compared with those of placebo in a double-blind crossover study in 21 normal adults. Salivary flow was measured immediately before administering study medications and 3 h after dosing, for the evaluation of anticholinergic activity. Mean salivary flow decreased significantly after administration of chlorpheniramine and atropine (P less than 0.01 and P less than 0.001, respectively), and was unchanged by terfenadine and placebo, indicating that terfenadine does not possess detectable anticholinergic activity. Mild drowsiness was reported by 57% and 29% of subjects who received chlorpheniramine and terfenadine, respectively.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2566537     DOI: 10.1177/030006058901700207

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  5 in total

Review 1.  Xerostomia and hyposalivation: causes, consequences and treatment in the elderly.

Authors:  T O Närhi; J H Meurman; A Ainamo
Journal:  Drugs Aging       Date:  1999-08       Impact factor: 3.923

Review 2.  Effects of antihistamine medications on exercise performance. Implications for sportspeople.

Authors:  L C Montgomery; P A Deuster
Journal:  Sports Med       Date:  1993-03       Impact factor: 11.136

Review 3.  H1-receptor antagonists. Comparative tolerability and safety.

Authors:  F E Simons
Journal:  Drug Saf       Date:  1994-05       Impact factor: 5.606

4.  Assessment of the anticholinergic effect of the new antihistamine mizolastine in healthy subjects.

Authors:  P Danjou; P Molinier; I Berlin; A Patat; P Rosenzweig; P L Morselli
Journal:  Br J Clin Pharmacol       Date:  1992-10       Impact factor: 4.335

Review 5.  Terfenadine. An updated review of its pharmacological properties and therapeutic efficacy.

Authors:  D McTavish; K L Goa; M Ferrill
Journal:  Drugs       Date:  1990-04       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.